|  |  | 

India Top Headlines

UK approval of Oxford-AstraZeneca Covid-19 vaccine positive news, awaiting approval from India: Serum Institute | India News


NEW DELHI: The Serum Institute of India (SII) on Wednesday called the approval of the Oxford-AstraZeneca Covid-19 vaccine in the UK as encouraging news and said the company would now await the final go-ahead for the drug in India.
Earlier in the day, the UK approved the Covid-19 vaccine developed by Oxford University scientists and produced by AstraZeneca for human use, the second coronavirus vaccine to be licensed for deployment in Britain after the shocks. from Pfizer / BioNTech.
The Oxford vaccine, which also has a link to IBS, was being evaluated by the British regulator, the Medicines and Healthcare Products Regulatory Agency (MHRA), after the government released the final cut of data last week.
“This is excellent and encouraging news. We will await final approval from Indian regulators,” SII CEO Adar Poonawalla said in a statement.
In order to introduce an urgently needed Covid-19 vaccine in India, SII, the world’s largest vaccine manufacturer, has established a collaboration with the University of Oxford and AstraZeneca to manufacture the vaccine.
The Pune-based company applied to the Comptroller General of Medicines of India (DCGI) for an emergency use authorization for the Covid-19 vaccine in the country.
The company has already stocked around 50 million doses of the vaccine and aims to produce up to 100 million doses per month by March of next year.
In addition to SII, Bharat Biotech and Pfizer have also applied to DCGI seeking emergency use authorization for their Covid-19 vaccines.
The approval of the vaccine by the MHRA means the vaccine is “safe and effective” and the government’s Department of Health and Social Care (DHSC) said the National Health Service (NHS) will give priority to administering the first of the two doses of the vaccine. those in higher risk groups quickly.
The vaccine, codenamed AZD1222 or ChAdOx1 nCoV-19, was developed at the University of Oxford with the support of the British-Swedish pharmaceutical giant AstraZeneca.
Britain has ordered 100 million doses of Oxford jab, with 40 million expected to be available by the end of March.
ChAdOx1 nCoV-19 is made from a virus (ChAdOx1), which is a weakened version of a common cold virus (adenovirus) that causes infections in chimpanzees, which has been genetically modified so that it is impossible for it to replicate in humans .
Once inside a human cell, the genetic instructions for the spike protein need to be “photocopied” many times, a process known as “transcription.”
Once the spike protein is produced, the immune system will react to it and this pre-trains the immune system to identify an actual Covid-19 infection. So when the vaccinated person is faced with the SARS-CoV-2 virus, their immune system is pre-trained and ready to attack it.

Reference page